Archives of Pharmacal Research

, Volume 38, Issue 12, pp 2120–2123 | Cite as

Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning

  • Minsoo Song
  • Seong-Heon Kim
  • Suk Kyoon Yoon
Report on Investigational Drugs


A new chimeric fusion transcript of KIF5B (the kinesin family 5B gene) and the RET (Rearranged during Transcription) oncogene, KIF5B-RET, was found in 1–2 % of lung adenocarcinomas (LADCs) in 2012. Several related clinical trials for non-small cell lung cancer (NSCLC) with KIF5B-RET rearrangements using existing RET inhibitors, such as cabozantinib, lenvatinib, vandetanib, sunitinib, ponatinib, and AUY922, have been swiftly initiated by the discovery of the KIF5B-RET fusion gene. Anti-RET activity and the status of clinical development of cabozantinib for KIF5B-RET fusion-positive NSCLC are discussed.


Cabozantinib KIF5B-RET Lung cancer Non-small cell lung cancer Adenocarcinoma Small-molecule tyrosine kinase inhibitor 



This research was supported by Bio & medical technology development program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2014M3A9D9033717).


  1. Christensen, J.G., H.Y. Zou, M.E. Arango, Q. Li, J.H. Lee, S.R. McDonnell, S. Yamazaki, G.R. Alton, B. Mroczkowski, and G. Los. 2007. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic largecell lymphoma. Molecular Cancer Therapeutics 6: 3314–3322.CrossRefPubMedGoogle Scholar
  2. Accessed 02 July 2015.
  3. Drilon, A., L. Wang, A. Hasanovic, Y. Suehara, D. Lipson, P. Stephens, J. Ross, V. Miller, M. Ginsberg, M.F. Zakowski, M.G. Kris, M. Ladanyi, and N. Rizvi. 2013. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discovery 3: 630–635.PubMedCentralCrossRefPubMedGoogle Scholar
  4. Drilon AE, Sima CS, Somwar R, Smith R, Ginsberg MS, Riely GJ, Rudin CM, Ladanyi M, Kris MG, Rizvi NA. Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers. Journal of Clinical Oncology 2015; 33: (suppl; abstr 8007).Google Scholar
  5. Fox, E., B.C. Widemann, M.K. Chuk, L.J. Marcus, A. Aikin, P. Whitcomb, M.J. Merino, M. Lodish, E. Dombi, S.M. Steinberg, S.A. Wells, and F.M. Balis. 2013. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clinical Cancer Research 19: 4239–4248.PubMedCentralCrossRefPubMedGoogle Scholar
  6. Ju, Y.S., W.-C. Lee, J.-Y. Shin, S. Lee, T. Bleazard, J.K. Won, Y.T. Kim, J.-I. Kim, J.-H. Kang, and J.-S. Seo. 2012. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Research 22: 436–445.PubMedCentralCrossRefPubMedGoogle Scholar
  7. Kohno, T., H. Ichikawa, Y. Totoki, K. Yasuda, M. Hiramoto, T. Nammo, H. Sakamoto, K. Tsuta, Y. Shimada, R. Iwakawa, H. Ogiwara, T. Oike, M. Enari, A.J. Schetter, H. Okayama, A. Haugen, V. Skaug, S. Chiku, I. Yamanaka, Y. Arai, S.-I. Watanabe, I. Sekine, S. Ogawa, C.C. Harris, H. Tsuda, T. Yoshida, J. Yokota, and T. Shibata. 2012. KIF5B-RET fusion in lung adenocarcinoma. Nature Medicine 18: 375–377.CrossRefPubMedGoogle Scholar
  8. Kohno, T., K. Tsuta, K. Tsuchihara, T. Nakaoku, K. Yoh, and K. Goto. 2013. RET fusion gene: Translation to personalized lung cancer therapy. Cancer Discovery 104: 1396–1400.Google Scholar
  9. Lipson, D., M. Capelletti, R. Yelensky, G. Otto, A. Parker, M. Jarosz, J.A. Curran, S. Balasubramanian, T. Bloom, K.W. Brennan, A. Donahue, S.R. Downing, G.M. Frampton, L. Garcia, F. Juhn, K.C. Mitchell, E. White, J. White, Z. Zwirko, T. Peretz, H. Nechushtan, L. Soussan-Gutman, J. Kim, H. Sasaki, H.R. Kim, S.-I. Park, D. Ercan, C.E. Sheehan, J.S. Ross, M.T. Cronin, P.A. Jänne, and P.J. Stephens. 2012. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nature Medicine 18: 382–384.PubMedCentralCrossRefPubMedGoogle Scholar
  10. Mano, H. 2012. ALKoma: A cancer subtype with a shared target. Cancer Discovery 2: 495–502.CrossRefPubMedGoogle Scholar
  11. Mologni, L. 2011. Development of RET kinase inhibitors for targeted cancer therapy. Current Medicinal Chemistry 18: 162–175.CrossRefPubMedGoogle Scholar
  12. Mulligan, L.M. 2014. RET revisited: expanding the oncogenic portfolio. Nature Review, Cancer 14: 173–186.CrossRefGoogle Scholar
  13. Santoro, M., R.M. Melillo, F. Carlomagno, G. Vecchio, and A. Fusco. 2004. Minireview: RET: Normal and abnormal functions. Endocrinology 145: 5448–5451.CrossRefPubMedGoogle Scholar
  14. Schoffski P, Elisei R, Muller S. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients with documented RECIST progression at baseline. Journal of Clinical Oncology 2012; 30: (suppl; abstr 5508).Google Scholar
  15. Soda, M., Y.L. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, S.-I. Fujiwara, H. Watanabe, K. Kurashina, H. Hatanaka, M. Bando, S. Ohno, Y. Ishikawa, H. Aburatani, T. Niki, Y. Sohara, Y. Sugiyama, and H. Mano. 2007. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561–566.CrossRefPubMedGoogle Scholar
  16. Song, M. 2015. Progress in the discovery of KIF5B-RET kinase inhibitors for the treatment of non-small lung cancer. Journal of Medicinal Chemistry 58: 3672–3681.CrossRefPubMedGoogle Scholar
  17. Takeuchi, K., M. Soda, Y. Togashi, R. Suzuki, S. Sakata, S. Hatano, R. Asaka, W. Hamanaka, H. Ninomiya, H. Uehara, Y.L. Choi, Y. Satoh, S. Okumura, K. Nakagawa, H. Mano, and Y. Ishikawa. 2012. RET, ROS1 and ALK fusion in lung cancer. Nature Medicine 18: 378–381.CrossRefPubMedGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2015

Authors and Affiliations

  1. 1.New Drug Development Center (NDDC), Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF)DaeguKorea

Personalised recommendations